ALX Oncology (ALXO) Q1 2026: 100% Response in CD47-High HER2+ Breast Cancer Underscores Biomarker Strategy
ALX Oncology’s Q1 2026 update marks a pivotal moment as new data show every centrally confirmed HER2-positive, CD47-high patient responded to EVO-based therapy, validating a biomarker-driven approach. The company’s pipeline advances on two fronts, with both the targeted antibody Evorpacept and the novel EGFR ADC, AOX 2004, meeting clinical and operational milestones. With financing secured and leadership strengthened, ALXO is positioned for multiple data catalysts and potential registrational studies by late 2027.
Summary
- Biomarker Validation: 100% response in CD47-high, HER2-positive breast cancer patients cements the targeted strategy.
- Pipeline Execution: Both Evorpacept and AOX 2004 remain on track for key clinical milestones and safety readouts.
- Commercial Readiness: Recent financing and operational hires enable ALXO to advance toward registrational trials and companion diagnostic development.
Business Overview
ALX Oncology is a clinical-stage biotechnology company focused on developing immuno-oncology therapies targeting the CD47 and EGFR pathways. Its lead program, Evorpacept (EVO), CD47-blocking fusion protein, is designed to enhance the efficacy of anti-cancer antibodies in solid tumors by blocking the “don’t eat me” signal. The second program, AOX 2004, EGFR-targeted antibody drug conjugate (ADC), aims to treat EGFR-expressing cancers with a differentiated payload and linker technology. ALXO generates revenue through out-licensing and partnerships, with the commercial model targeting high-unmet-need oncology segments.
Performance Analysis
Q1 2026 saw ALXO deliver on multiple fronts, highlighted by compelling clinical data and operational progress. The most striking result was the 100% objective response rate in CD47-high, centrally confirmed HER2-positive metastatic breast cancer patients treated with EVO in combination with Zanidatamab. This cohort, heavily pretreated with a median of five prior lines of therapy, achieved a median duration of response of 20 months and progression-free survival (PFS) of 22 months, vastly exceeding historical benchmarks for this patient population.
Beyond efficacy, the company’s safety data on Evorpacept—now encompassing over 800 treated patients—continues to support its differentiated mechanism, avoiding the on-target toxicities that plagued prior CD47 inhibitors. The ongoing phase 2 Aspen 09 breast cancer trial is enrolling robustly, with interim data from 80 patients expected mid-2027. Meanwhile, AOX 2004, the EGFR ADC, is progressing through dose escalation with an initial safety readout planned for the second half of 2026. ALXO’s February financing, anchored by leading investors, ensures capital runway through key data milestones.
- Biomarker-Driven Efficacy: All CD47-high, HER2-positive patients responded, with durable benefit far above standard of care.
- Operational Milestone Delivery: Enrollment and site activation for both lead programs remain ahead of schedule, supporting clinical timelines.
- Financial Strength: Recent financing supports execution through upcoming data readouts and potential pivotal trial initiation.
ALXO’s execution this quarter strengthens its position in an increasingly competitive immuno-oncology landscape, with both clinical and operational momentum supporting its targeted oncology thesis.
Executive Commentary
"With this new data today, we have now demonstrated in two studies in two HER2-positive cancers that EVO is a very active drug and that a CD47-targeted approach can drive transformational benefit to patients."
Jason Letman, CEO
"Our clinical safety database is now more than 800 avorpicep-treated patients. And it also, the clinical safety data is also entirely consistent with this mechanism of action that we show here."
Barb Quincy, Chief Medical Officer
Strategic Positioning
1. Biomarker-Driven Patient Selection
ALXO’s strategy centers on identifying and treating patients most likely to benefit from its therapies, using CD47 expression as a predictive biomarker. The latest data reinforce that high CD47 expression correlates with superior response rates and durability, supporting a precision medicine approach. This focus underpins the design of the ongoing Aspen 09 trial and informs the development of a companion diagnostic with Ventana Laboratory.
2. Dual Pipeline Advancement
The company is advancing two independent yet synergistic programs: Evorpacept for HER2-positive solid tumors and AOX 2004 for EGFR-expressing cancers. Both address historically challenging targets, with differentiated mechanisms and safety profiles. ALXO’s ability to progress both assets in parallel, while maintaining clinical timelines, increases its optionality and de-risks its overall platform.
3. Capital and Operational Scaling
Recent financing and the addition of Jeff Knight as Chief Development and Operating Officer bolster ALXO’s readiness for late-stage development and potential commercialization. The company is scaling its clinical and operational infrastructure in anticipation of pivotal trials and future product launches, signaling a transition from early-stage biotech to a more mature, execution-focused organization.
4. Regulatory and Commercial Pathways
ALXO is planning for a phase 3, registrational trial in a pre-selected, biomarker-positive population, while keeping the door open for accelerated approval if response rates in Aspen 09 are extraordinary. The company is actively developing a companion diagnostic to enable efficient patient identification and market adoption upon approval.
Key Considerations
This quarter’s results highlight both ALXO’s scientific validation and the operational groundwork for a pivotal period ahead.
Key Considerations:
- Durability of Benefit: The 20-month duration of response and 22-month PFS in CD47-high patients represent a step-change versus historical controls.
- Companion Diagnostic Development: Partnership with Ventana aims to ensure CD47 testing is available for patient selection in phase 3 and at commercial launch.
- Cutoff Optimization: Ongoing trials will refine the optimal CD47 expression threshold, balancing efficacy with commercial opportunity.
- EGFR ADC Progression: AOX 2004’s dose escalation and upcoming safety data offer a second, independent catalyst for the platform.
Risks
Key risks include the small sample size of current efficacy cohorts and the need for confirmation in larger, prospective studies. Regulatory hurdles for accelerated approval are significant, especially for combination regimens and retrospective biomarker application. The commercial success of ALXO’s therapies will depend on the robustness of the companion diagnostic and payer acceptance. Competitive pressures in the immuno-oncology field and the evolving HER2 treatment landscape also pose ongoing challenges.
Forward Outlook
For the next quarter, ALXO guided to:
- Continued enrollment and operational progress in Aspen 09 (Evorpacept, HER2+ breast cancer)
- Advancement of AOX 2004 through dose escalation, with safety data expected in the second half of 2026
For full-year 2026, management maintained guidance:
- Interim top-line data from approximately 80 Aspen 09 patients by mid-2027
- Readiness for registrational studies for both lead programs by end of 2027
Management highlighted several factors that will shape the next phases:
- Refining CD47 cutoff and companion diagnostic for patient selection
- Potential for phase 3 trial initiation contingent on interim results
Takeaways
ALXO’s Q1 2026 results signal a potential inflection point for its biomarker-driven oncology strategy.
- Transformational Efficacy: 100% response in CD47-high, HER2-positive breast cancer patients positions EVO as a best-in-class candidate if replicated in larger trials.
- Operational Execution: Pipeline progress and strengthened leadership set the stage for late-stage development and future commercialization.
- Upcoming Catalysts: Investors should watch for Aspen 09 interim data, AOX 2004 safety results, and companion diagnostic milestones as key inflection points through 2027.
Conclusion
ALXO’s Q1 2026 update demonstrates strong clinical validation for its CD47-targeted approach and operational readiness for late-stage development. The company’s focused execution and robust financing position it to capitalize on multiple upcoming data catalysts, with the potential to reshape the treatment paradigm for HER2-positive and EGFR-expressing cancers.
Industry Read-Through
ALXO’s biomarker-driven strategy and durable efficacy in heavily pretreated patients highlight the increasing importance of precision medicine in oncology. The validation of CD47 as a predictive biomarker may prompt other immuno-oncology developers to accelerate companion diagnostic programs and refine patient selection criteria. The evolving HER2-positive breast cancer landscape, especially post-TDXD, underscores the need for novel mechanisms and targeted approaches. As ALXO advances, competitors in the antibody drug conjugate and checkpoint inhibitor space will need to demonstrate similar clinical differentiation and operational agility to remain competitive.